MGI(SH:688114) Zheng Quan Zhi Xing·2025-08-22 16:48Core Viewpoint - The company has revised its 2024 Restricted Stock Incentive Plan and Employee Stock Ownership Plan to enhance employee motivation and align with its strategic goals, particularly focusing on increasing market share in the gene sequencing industry [1][11]. Group 1: Decision Process and Disclosure - The company has completed the necessary decision-making procedures and disclosures for the 2024 Restricted Stock Incentive Plan and Employee Stock Ownership Plan, which require approval from the shareholders' meeting to be implemented [2][12]. - The supervisory board has verified the related matters of the incentive plan and provided relevant opinions [4][11]. Group 2: Reasons for Revision - The revision aims to adapt to changes in the external environment and the company's actual situation, adding performance assessment indicators related to the sales volume of gene sequencers excluding related parties [6][10]. - The company believes that capturing market share in gene sequencer sales is crucial for driving subsequent reagent sales and revenue growth [6][10]. Group 3: Revised Content - The revised performance assessment indicators now include the sales volume of gene sequencers excluding related parties, with specific targets set for the first and second vesting periods [7][9]. - The performance completion rates and corresponding vesting ratios have been adjusted to reflect the new assessment criteria [8][9]. Group 4: Impact of Revisions - The revisions are expected to effectively motivate employees and support the company's strategic and operational goals without adversely affecting its financial status or operational performance [11][12]. - The adjustments are designed to enhance the company's competitiveness and market coverage, particularly in the context of increasing pressure from macroeconomic factors and competition [10][11].